Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amgen's Enterprise Value is $167,827 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $11,220 Mil. Therefore, Amgen's EV-to-EBIT ratio for today is 14.96.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Amgen's Enterprise Value is $167,827 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $14,822 Mil. Therefore, Amgen's EV-to-EBITDA ratio for today is 11.32.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Amgen's Enterprise Value is $167,827 Mil.
Amgen's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $26,833 Mil. Therefore, Amgen's EV-to-Revenue ratio for today is 6.25.
Amgen Enterprise Value Historical Data
The historical data trend for Amgen's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Enterprise Value
127,189.23
163,560.80
155,301.74
150,872.75
169,889.76
Amgen Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Enterprise Value
147,476.90
169,889.76
159,201.03
146,054.50
169,540.48
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Enterprise Value Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Amgen's Enterprise Value falls into.
Amgen Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Amgen's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Amgen's current Enterprise Value is $167,827 Mil.
Amgen's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11,220 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Amgen's current Enterprise Value is $167,827 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,822 Mil.
Amgen's current Enterprise Value is $167,827 Mil.
Amgen's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $26,833 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen Enterprise Value Related Terms
Thank you for viewing the detailed overview of Amgen's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
1.08(0.41%) Volume: 1,978,454 8:08PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 